The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Open accessAbstract
Purpose: Foretinib is an oral multikinase inhibitor targeting MET, VEGF, RON, AXL, and TIE-2 receptors. Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC. Patients and Methods: Patients were enrolled onto the study in two cohorts with different dosing schedules of foretinib: cohort A, 240 mg once per day on days 1 through 5 every 14 days (intermittent arm); cohort B, 80 mg daily (daily dosing arm). Patients were stratified on the basis of MET pathway activation (germline or somatic MET mutation, MET [7q31] amplification, or gain of chromosome 7). The primary end point was overall response rate (ORR). Results: Overall, 74 patients were enrolled, with 37 in each dosing cohort. ORR by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 was 13.5%, median progression-free survival was 9.3 months, and median overall survival was not reached. The presence of a germline MET mutation was highly predictive of a response (five of 10 v five of 57 patients with and without germline MET mutations, respectively). The most frequent adverse events of any grade associated with foretinib were fatigue, hypertension, gastrointestinal toxicities, and nonfatal pulmonary emboli. Conclusion: Foretinib demonstrated activity in patients with advanced PRCC with a manageable toxicity profile and a high response rate in patients with germline MET mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Brocken, P., van der Heijden, H. F. M., Dekhuijzen, P. N. R., Peters-Bax, L., & de Geus-Oei, L.-F. (2014) · Respiration · doi:10.1159/000347096 · Cited by 4,002
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
(2014) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/jwiet-2014-0117 · Cited by 2,473
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Self-citationNalluri, S. R., Chu, D., Keresztes, R., Zhu, X., & Wu, S. (2008) · JAMA · doi:10.1001/jama.2008.656 · Cited by 771
Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors.
Delahunt, B., & Eble, J. N. (1997) · PubMed · Cited by 714
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
Gore, M. E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G. A., Oudard, S., Hariharan, S., Lee, S.-H., Haanen, J., Castellano, D., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70162-7 · Cited by 589
Self-citationNovel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497
Self-citationEfficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
Choueiri, T. K., Plantade, A., Elson, P. J., Négrier, S., Ravaud, A., Oudard, S. M., Zhou, M., Rini, B. I., Bukowski, R. M., & Escudier, B. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.3223 · Cited by 393
Self-citationQian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
Dutcher, J. P., de Souza, P., McDermott, D., Figlin, R. A., Berkenblit, A., Thiele, A., Krygowski, M., Strahs, A., Feingold, J., & Hudes, G. (2009) · Medical Oncology · doi:10.1007/s12032-009-9177-0 · Cited by 257
Self-citationStadler, W. M., Figlin, R. A., McDermott, D. F., Dutcher, J. P., Knox, J. J., Miller, W. H., Hainsworth, J. D., Henderson, C., George, J. R., Hajdenberg, J. J., et al. (2010) · Cancer · doi:10.1002/cncr.24864 · Cited by 255
Self-citationEder, J. P., Shapiro, G. I., Appleman, L. J., Zhu, A. X., Miles, D., Keer, H., Cancilla, B., Chu, F., Hitchcock-Bryan, S., Sherman, L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0574 · Cited by 197
Self-citationA Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma
Tannir, N. M., Plimack, E., Ng, C., Tamboli, P., Bekele, N. B., Xiao, L., Smith, L., Lim, Z., Pagliaro, L., Araujo, J., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.06.043 · Cited by 164
Vaklavas, C., Lenihan, D. J., Kurzrock, R., & Tsimberidou, A. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0252 · Cited by 130
Data Analysis and Interpretation
(2012) · Sage eBooks · doi:10.4135/9781483384511.n8 · Cited by 120
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
Molina, A. M., Feldman, D. R., Ginsberg, M. S., Kroog, G. S., Tickoo, S. K., Jia, X., Georges, M., Patil, S., Baum, M. S., Reuter, V. E., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9491-6 · Cited by 87
Shapiro, G. I., McCallum, S. W., Adams, L. M., Sherman, L. J., Weller, S., Swann, S., Keer, H. N., Miles, D., Müller, T. R., Rabe, D. C., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0287-6 · Cited by 40
Self-citation
Cited by
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Self-citationTreatment of renal cell carcinoma: Current status and future directions
Barata, P. C., & Rini, B. I. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21411 · Cited by 831
Self-citationFrampton, G. M., Ali, S. M., Rosenzweig, M., Chmielecki, J., Lu, X., Bauer, T. M., Akimov, M., Bufill, J. A., Lee, C., Jentz, D., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0285 · Cited by 796
Zhang, Y., Xia, M., Jin, K., Wang, S., Wei, H., Fan, C., Wu, Y., Li, X., Li, X., Li, G., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0796-y · Cited by 572
Metadata
- Authors
- Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., Ottesen, L. H., Laubscher, K. H., Sherman, L., McDermott, D. F., Haas, N. B., Flaherty, K. T., Ross, R., Eisenberg, P., Meltzer, P. S., Merino, M. J., Bottaro, D. P., Linehan, W. M., & Srinivasan, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-01-10
- Volume
- 31
- Issue
- 2
- Pages
- 181-186
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116095691
- Cited by
- 463
- References
- 22
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.